This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Kyowa Hakko Kirin Co., Limited, Kyowa Kirin Co., Ltd., La Jolla Institute for Allergy and Immunology. Active years: 2012-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- La Jolla, CA (US) (2013)
- San Diego, CA (US) (2012 - 2021)
Company Filing History:
4 out of 272 
3 out of 46 
2 out of 62 
Years Active: 2012-2025
Title: Rachel Soloff Nugent: Innovator in Antibody Development
Introduction
Rachel Soloff Nugent is a prominent inventor based in San Diego, California. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of seven patents to her name, her work has advanced the understanding and application of antibody technology.
Latest Patents
Among her latest patents is the invention of a human monoclonal antibody targeting human CD134 (OX40). This invention provides antibodies that specifically bind to OX40, referred to as OX40 antibodies, anti-OX40, or anti-OX40 antibodies. The antibodies include mammalian, humanized, and chimeric variants, which are useful in various methods, including treatment, screening, and detection. Another notable patent involves FN14 antibodies, which are designed to bind to Fn14, acting as antagonists and non-agonists of Fn14.
Career Highlights
Rachel has worked with notable companies in the biotechnology sector, including Kyowa Hakko Kirin Co., Limited and Kyowa Kirin Co., Ltd. Her expertise in antibody development has positioned her as a key player in the industry, contributing to innovative solutions in therapeutic applications.
Collaborations
Throughout her career, Rachel has collaborated with esteemed colleagues such as Shinichiro Kato and Hitoshi Yoshida. These partnerships have further enhanced her research and development efforts in the field of monoclonal antibodies.
Conclusion
Rachel Soloff Nugent's contributions to antibody technology exemplify her innovative spirit and dedication to advancing medical science. Her patents and collaborations reflect her significant impact on the biotechnology industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile